SAFETY STUDY OF ROMIPLOSTIM BIOSIMILAR
Idiopathic thrombocytopenic purpura is a chronic autoimmune hematological disease caused by an increased destruction of platelets and associated thrombocytopenia, for the treatment of which the imported drug romiplostim is used. Сreation of the drug biosimilar provides a reduction in the cost of the...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Volgograd State Medical University, Pyatigorsk Medical and Pharmaceutical Institute
2022-10-01
|
| Series: | Фармация и фармакология (Пятигорск) |
| Subjects: | |
| Online Access: | https://www.pharmpharm.ru/jour/article/view/1165 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849242077062234112 |
|---|---|
| author | A. N. Afanasyeva V. B. Saparova D. D. Karal-Ogly E. I. Mukhametzyanova D. V. Kurkin A. V. Kalatanova I. E. Makarenko A. L. Khokhlov I. A. Lugovik |
| author_facet | A. N. Afanasyeva V. B. Saparova D. D. Karal-Ogly E. I. Mukhametzyanova D. V. Kurkin A. V. Kalatanova I. E. Makarenko A. L. Khokhlov I. A. Lugovik |
| author_sort | A. N. Afanasyeva |
| collection | DOAJ |
| description | Idiopathic thrombocytopenic purpura is a chronic autoimmune hematological disease caused by an increased destruction of platelets and associated thrombocytopenia, for the treatment of which the imported drug romiplostim is used. Сreation of the drug biosimilar provides a reduction in the cost of therapy and an access for the treatment to more patients.The aim of the study was to compare the safety indicators of the reference drug and its biosimilar in vivo and in vitro.Materials and methods. In the in vitro study, a model of “complement-dependent cytotoxicity” induced by the complement was formed on the 32D hTPOR clone 63-cell line, followed by a cell viability measurement with the CellTitter Glo® kit. An in vivo part of the study was carried out on Javanese macaque monkeys (Macaca fascicularis). During the experiment, the clinical condition, mortality, appetite of the animals, their body weight, body temperature, respiratory rate were assessed, the clinical parameters of blood and urine of the animals were also monitored, and the hemostasis indicators were additionally measured.Results. In the in vitro experiment, the original drug romiplostim and its biosimilar GP40141 were compared in terms of EC50 values. The indicatirs did not show complement-dependent cytotoxicity. According to the in vivo results, no deviations were recorded in the clinical status of the animals and their feed intake, and no lethality was fixed out in the groups either. For all the parameters studied (body weight and temperature, respiratory rate, clinical urinalysis, clinical and biochemical blood tests, coagulation hemostasis), GP40141 and romiplostim, when administered at the doses equivalent to 10 toxic doses (TDs), had comparable effects.Conclusion. In the comparison of safety performance both in vitro and in vivo, the original drug romiplostim and its biosimilar GP40141 showed similar results. |
| format | Article |
| id | doaj-art-a5cc49ccab96497c88981a4904fcda8c |
| institution | Kabale University |
| issn | 2307-9266 2413-2241 |
| language | Russian |
| publishDate | 2022-10-01 |
| publisher | Volgograd State Medical University, Pyatigorsk Medical and Pharmaceutical Institute |
| record_format | Article |
| series | Фармация и фармакология (Пятигорск) |
| spelling | doaj-art-a5cc49ccab96497c88981a4904fcda8c2025-08-20T03:59:56ZrusVolgograd State Medical University, Pyatigorsk Medical and Pharmaceutical InstituteФармация и фармакология (Пятигорск)2307-92662413-22412022-10-0110435437010.19163/2307-9266-2022-10-4-354-370449SAFETY STUDY OF ROMIPLOSTIM BIOSIMILARA. N. Afanasyeva0V. B. Saparova1D. D. Karal-Ogly2E. I. Mukhametzyanova3D. V. Kurkin4A. V. Kalatanova5I. E. Makarenko6A. L. Khokhlov7I. A. Lugovik8Сlosed Joint-Stock Company “Farm-Holding”Сlosed Joint-Stock Company “Farm-Holding”; A.I. Yevdokimov Moscow State University of Medicine and DentistryScientific Research Institute of Medical PrimatologyScientific Research Institute of Medical PrimatologyVolgograd State Medical UniversityСlosed Joint-Stock Company “Farm-Holding”Сlosed Joint-Stock Company “Farm-Holding”; A.I. Yevdokimov Moscow State University of Medicine and DentistryYaroslavl State Medical UniversityСlosed Joint-Stock Company “Farm-Holding”Idiopathic thrombocytopenic purpura is a chronic autoimmune hematological disease caused by an increased destruction of platelets and associated thrombocytopenia, for the treatment of which the imported drug romiplostim is used. Сreation of the drug biosimilar provides a reduction in the cost of therapy and an access for the treatment to more patients.The aim of the study was to compare the safety indicators of the reference drug and its biosimilar in vivo and in vitro.Materials and methods. In the in vitro study, a model of “complement-dependent cytotoxicity” induced by the complement was formed on the 32D hTPOR clone 63-cell line, followed by a cell viability measurement with the CellTitter Glo® kit. An in vivo part of the study was carried out on Javanese macaque monkeys (Macaca fascicularis). During the experiment, the clinical condition, mortality, appetite of the animals, their body weight, body temperature, respiratory rate were assessed, the clinical parameters of blood and urine of the animals were also monitored, and the hemostasis indicators were additionally measured.Results. In the in vitro experiment, the original drug romiplostim and its biosimilar GP40141 were compared in terms of EC50 values. The indicatirs did not show complement-dependent cytotoxicity. According to the in vivo results, no deviations were recorded in the clinical status of the animals and their feed intake, and no lethality was fixed out in the groups either. For all the parameters studied (body weight and temperature, respiratory rate, clinical urinalysis, clinical and biochemical blood tests, coagulation hemostasis), GP40141 and romiplostim, when administered at the doses equivalent to 10 toxic doses (TDs), had comparable effects.Conclusion. In the comparison of safety performance both in vitro and in vivo, the original drug romiplostim and its biosimilar GP40141 showed similar results.https://www.pharmpharm.ru/jour/article/view/1165romiplostimbiosimilar gp40141nplate®complement-dependent cytotoxicitydrug safety studiesin vivoin vitroidiopathic thrombocytopenic purpuratoxicological profilethrombopoietin receptortpo-r |
| spellingShingle | A. N. Afanasyeva V. B. Saparova D. D. Karal-Ogly E. I. Mukhametzyanova D. V. Kurkin A. V. Kalatanova I. E. Makarenko A. L. Khokhlov I. A. Lugovik SAFETY STUDY OF ROMIPLOSTIM BIOSIMILAR Фармация и фармакология (Пятигорск) romiplostim biosimilar gp40141 nplate® complement-dependent cytotoxicity drug safety studies in vivo in vitro idiopathic thrombocytopenic purpura toxicological profile thrombopoietin receptor tpo-r |
| title | SAFETY STUDY OF ROMIPLOSTIM BIOSIMILAR |
| title_full | SAFETY STUDY OF ROMIPLOSTIM BIOSIMILAR |
| title_fullStr | SAFETY STUDY OF ROMIPLOSTIM BIOSIMILAR |
| title_full_unstemmed | SAFETY STUDY OF ROMIPLOSTIM BIOSIMILAR |
| title_short | SAFETY STUDY OF ROMIPLOSTIM BIOSIMILAR |
| title_sort | safety study of romiplostim biosimilar |
| topic | romiplostim biosimilar gp40141 nplate® complement-dependent cytotoxicity drug safety studies in vivo in vitro idiopathic thrombocytopenic purpura toxicological profile thrombopoietin receptor tpo-r |
| url | https://www.pharmpharm.ru/jour/article/view/1165 |
| work_keys_str_mv | AT anafanasyeva safetystudyofromiplostimbiosimilar AT vbsaparova safetystudyofromiplostimbiosimilar AT ddkaralogly safetystudyofromiplostimbiosimilar AT eimukhametzyanova safetystudyofromiplostimbiosimilar AT dvkurkin safetystudyofromiplostimbiosimilar AT avkalatanova safetystudyofromiplostimbiosimilar AT iemakarenko safetystudyofromiplostimbiosimilar AT alkhokhlov safetystudyofromiplostimbiosimilar AT ialugovik safetystudyofromiplostimbiosimilar |